The Future of Hodgkin Lymphoma -- Brentuximab and Beyond

Dr Bruce Cheson and Dr Ann LaCasce highlight data from ASH 2014 on brentuximab vedotin and discuss promising agents for Hodgkin lymphoma, including checkpoint inhibitors nivolumab and pembrolizumab.

Source: Medscape Oncology - December 18, 2014 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts